6361:TSEEbara Corporation Analysis
Data as of 2026-03-13 - not real-time
¥4,835.00
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Ebara Corp is trading at ¥4,835, which sits below its 20‑day (¥5,367) and 50‑day (¥4,951) simple moving averages but remains comfortably above the 200‑day average (¥3,655), indicating a short‑term pullback within a longer‑term uptrend. The technical landscape shows a bullish trend direction yet a bearish MACD crossover (MACD line well under the signal) and a neutral RSI around 42, suggesting limited upside momentum. Volume has been trending down, and the 30‑day volatility is high at roughly 57%, while a beta of 1.12 points to slightly higher market sensitivity. Valuation metrics reveal a trailing P/E of 30.6, modestly above the industry average of 29.1, and a price‑to‑book of 4.34, indicating premium pricing. The DCF‑derived fair value of ¥678 is dramatically lower than the current price, flagging the stock as potentially overvalued. Dividend yield sits at 1.3% with a payout ratio near 35%, which appears sustainable given operating cash flow, though free cash flow is negative due to capital intensity. Debt‑to‑equity stands at 43%, a relatively high leverage level for an industrial firm, adding balance‑sheet pressure. Overall, the company delivers stable revenues with zero growth, solid operating margins, but limited earnings acceleration, positioning it more as a value play rather than a growth catalyst.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price below short‑term moving averages
- Bearish MACD signal
- Decreasing trading volume
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Valuation premium to peers
- Modest dividend yield with sustainable payout
- High leverage and negative free cash flow
Long Term
> 3 yearsCautious
Model confidence: 7/10
Key Factors
- Significant overvaluation relative to DCF fair value
- Limited earnings growth prospects
- Elevated debt level increasing financial risk
Key Metrics & Analysis
Financial Health
Profit Margin8.00%
P/E Ratio30.6
ROE15.81%
ROA6.82%
Debt/Equity43.08
P/B Ratio4.3
Op. Cash Flow¥40.8B
Free Cash Flow¥-63279374336
Industry P/E29.1
Technical Analysis
TrendBullish
RSI42.0
Support¥4,609.00
Resistance¥5,919.00
MA 20¥5,366.70
MA 50¥4,951.16
MA 200¥3,654.63
MACDBearish
VolumeDecreasing
Fear & Greed Index72.54
Valuation
Fair Value¥678.16
Target Price¥5,364.00
Upside/Downside10.94%
GradeOvervalued
TypeValue
Dividend Yield1.30%
Risk Assessment
Beta1.12
Volatility56.95%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.